Medifast experienced a challenging fourth quarter in 2025, with revenue decreasing by 36.9% to $75.1 million and reporting a net loss of $18.1 million. This loss was significantly impacted by a $12.1 million non-cash valuation allowance on deferred tax assets. The decline was largely attributed to a 40.6% decrease in active earning coaches, although coach productivity showed a positive year-over-year trend for the first time since 2022.

Medifast experienced a significant decline in its third-quarter 2025 financial results, with revenue decreasing by 36.2% to $89.4 million and reporting a net loss of $2.3 million. This downturn was largely attributed to a 35.0% decrease in active earning OPTAVIA coaches, impacted by the growing acceptance of GLP-1 medications for weight loss. Despite the challenges, the company maintains a strong balance sheet with $173.5 million in cash and no debt, and is strategically shifting its focus towards metabolic health.

Medifast experienced a challenging second quarter in 2025, with revenue decreasing by 37.4% to $105.6 million and net income falling to $2.5 million. The decline was largely attributed to a significant reduction in the number of active earning OPTAVIA coaches and lower average revenue per coach, reflecting broader market challenges including the impact of GLP-1 medications.

Medifast reported a significant decrease in revenue and a net loss for the first quarter of 2025, primarily driven by a decrease in the number of active earning OPTAVIA coaches. Despite the challenges, the company maintains a strong balance sheet with substantial cash reserves and no debt.

Medifast announced its fourth quarter and full year 2024 financial results, with Q4 revenue decreasing 37.7% to $119.0 million from $191.0 million in Q4 2023, primarily due to a decrease in active earning OPTAVIA coaches and lower coach productivity. Net income for Q4 2024 was $0.8 million, or $0.07 per diluted share.

Medifast's Q3 2024 revenue decreased by 40.6% to $140.2 million compared to Q3 2023. The company reported a net income of $1.1 million, or $0.10 per diluted share, and a non-GAAP adjusted EPS of $0.35. The decline was primarily due to a decrease in active earning OPTAVIA coaches and lower coach productivity.

Medifast reported a revenue of $168.6 million for Q2 2024, a 43.1% decrease compared to Q2 2023. The company experienced a net loss of $8.2 million, or $0.75 per diluted share, but a non-GAAP adjusted net income of $10.1 million, or $0.92 per diluted share. The results reflect strategic transformation efforts, including a focus on new customer acquisition and a broader health and wellness offer.

Medifast reported a decrease in revenue to $174.7 million, driven by a decline in active OPTAVIA Coaches and lower coach productivity. Net income was $8.3 million, with EPS at $0.76. The company is focusing on transforming its OPTAVIA offer to include support for consumers using medical weight loss solutions and investing in company-led customer acquisition initiatives.

Medifast's Q4 2023 revenue decreased by 43.4% to $191.0 million compared to Q4 2022. Net income also decreased to $6.0 million, or $0.55 per diluted share. The decline was primarily due to a decrease in the number of active earning OPTAVIA Coaches and a decline in productivity per coach. The company is focusing on business realignment and investments in customer acquisition and medically-supported weight loss.

Medifast reported a decrease in revenue to $235.9 million, a net income of $23.1 million, and an EPS of $2.12 for the third quarter of 2023. The company faced challenges with a decline in active earning OPTAVIA Coaches and their productivity, but is adapting its business model to address the evolving health and wellness market.

Medifast reported a decrease in revenue for Q2 2023, driven by a decline in active OPTAVIA Coaches and their productivity. However, strategic initiatives focused on efficiency and cost reduction helped mitigate the impact of economic headwinds. The company is also advancing its health and wellness agenda with the launch of new products and pilot programs.

Medifast reported a revenue of $349.0 million for Q1 2023, a decrease of 16.4% compared to Q1 2022. EPS was $3.67, and net income was $40.0 million. The company's balance sheet remains strong with $123.7 million in cash and cash equivalents and no interest-bearing debt.

Medifast's Q4 2022 saw a revenue decrease of 10.7% to $337.2 million, but the number of active earning OPTAVIA Coaches increased by 1.8% to 60,900. Net income was $26.5 million, or $2.41 per diluted share, while non-GAAP adjusted EPS was $3.70. The company is focused on driving productivity and Coach growth, as well as mitigating cost pressures.

Medifast's Q2 2022 revenue increased by 15.0% to $453.3 million, driven by a 14.9% increase in active earning OPTAVIA Coaches to 68,000. Revenue per coach slightly increased. Net income decreased by 16.7% to $39.1 million, and EPS decreased by 13.6% to $3.42. The company has updated its full-year 2022 revenue guidance to $1.58 billion to $1.66 billion.

Medifast, Inc. reported record quarterly revenues with a 22.6% increase, driven by a 21.7% growth in active earning OPTAVIA Coaches and a 1.3% increase in revenue per coach. The company also raised its annual revenue and EPS guidance.

Medifast reported strong Q4 2021 results, with a 42.6% increase in revenue to $377.8 million compared to the prior-year period. The company's EPS increased by 23.3% to $2.91. The growth was driven by an increase in active earning OPTAVIA Coaches and their productivity.

Medifast reported strong third-quarter results with a 52.3% increase in revenue to $413.4 million. The number of active OPTAVIA Coaches rose by 44.9% to 61,000, and average revenue per coach increased by 7.0% to $6,773. Net income was $42.0 million, or $3.56 per diluted share.

Medifast, Inc. reported a significant increase in revenue for the second quarter of 2021, with a 79.2% increase to $394.2 million. This growth was largely driven by the success of independent OPTAVIA Coaches. The company is positioned to deliver on its 2021 goals and long-term profitable growth.

Medifast reported a significant increase in revenue and earnings for the first quarter of 2021. Revenue increased by 90.9% to $340.7 million, driven by a rise in active OPTAVIA Coaches and increased productivity. Net income also saw a substantial increase, reaching $41.1 million, or $3.46 per diluted share.

Medifast, Inc. announced a 55.3% increase in fourth-quarter revenue to $264.9 million, driven by a 39.0% increase in active OPTAVIA Coaches and a rise in average revenue per coach. Net income rose to $28.0 million, or $2.36 per diluted share.

Medifast reported a strong third quarter with a 42.8% increase in revenue, driven by growth in active OPTAVIA Coaches and increased revenue per coach. Net income also saw a significant increase.

Medifast reported a revenue increase of 17.6% to $220.0 million compared to the second quarter of 2019. The number of active earning OPTAVIA Coaches increased by 19.3% to 36,500. EPS increased to $1.86, and non-GAAP adjusted EPS increased to $1.96.

Medifast reported a strong start to the year with revenue and EPS exceeding guidance, driven by a record number of active earning OPTAVIA coaches. The company's financial model and balance sheet position it for long-term growth, with encouraging trends as the OPTAVIA coach community adapts to new ways of working.

Medifast reported a 17% increase in revenue to $170.6 million and a 32% increase in active earning OPTAVIA Coaches to 31,800 in Q4 2019. Net income increased by 27% to $19.9 million, with EPS rising by 27.7% to $1.66. The company also declared a quarterly cash dividend of $1.13 per share.